| Literature DB >> 30563885 |
Kameshwar Prasad1, Reed Siemieniuk2,3, Qiukui Hao2,4, Gordon Guyatt2,5, Martin O'Donnell6, Lyubov Lytvyn2, Anja Fog Heen7, Thomas Agoritsas2,8, Per Olav Vandvik7,9, Sankar Prasad Gorthi10, Loraine Fisch11, Mirza Jusufovic12, Jennifer Muller13,14, Brenda Booth13, Eleanor Horton15, Auxiliadora Fraiz, Jillian Siemieniuk16, Awah Cletus Fobuzi17, Neelima Katragunta18, Bram Rochwerg19,5.
Abstract
WHAT IS THE ROLE OF DUAL ANTIPLATELET THERAPY AFTER HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKE? SPECIFICALLY, DOES DUAL ANTIPLATELET THERAPY WITH A COMBINATION OF ASPIRIN AND CLOPIDOGREL LEAD TO A GREATER REDUCTION IN RECURRENT STROKE AND DEATH OVER THE USE OF ASPIRIN ALONE WHEN GIVEN IN THE FIRST 24 HOURS AFTER A HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR ISCHAEMIC STROKE? AN EXPERT PANEL PRODUCED A STRONG RECOMMENDATION FOR INITIATING DUAL ANTIPLATELET THERAPY WITHIN 24 HOURS OF THE ONSET OF SYMPTOMS, AND FOR CONTINUING IT FOR 10-21 DAYS CURRENT PRACTICE IS TYPICALLY TO USE A SINGLE DRUG. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30563885 DOI: 10.1136/bmj.k5130
Source DB: PubMed Journal: BMJ ISSN: 0959-8138